Orgenesis Inc. Income from Discontinued Operations

Income from Discontinued Operations of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Income from Discontinued Operations growth rates and interactive chart.


Highlights and Quick Summary

  • Income from Discontinued Operations for the quarter ending December 30, 2020 was $5.39 Million (a -24.45% decrease compared to previous quarter)
  • Year-over-year quarterly Income from Discontinued Operations decreased by -92.95%
  • Annual Income from Discontinued Operations for 2020 was $95.7 Million (a -2872.48% decrease from previous year)
  • Annual Income from Discontinued Operations for 2019 was $-3.45 Million (a -Infinity% decrease from previous year)
  • Twelve month Income from Discontinued Operations ending December 30, 2020 was $95.7 Million (a 7.94% increase compared to previous quarter)
  • Twelve month trailing Income from Discontinued Operations increased by 30.87% year-over-year
Trailing Income from Discontinued Operations for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
$95.7 Million $88.7 Million $80.8 Million $73.1 Million
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Income from Discontinued Operations of Orgenesis Inc.

Most recent Income from Discontinued Operationsof ORGS including historical data for past 10 years.

Interactive Chart of Income from Discontinued Operations of Orgenesis Inc.

Orgenesis Inc. Income from Discontinued Operations for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $5.39 $7.13 $6.72 $76.47 $95.71
2019 $-1.65 $-0.73 $-0.95 $-0.12 $-3.45
2017 $0.0
2016 $0.0 $0.0
2012 $0.0

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.